We Screen Biotech Companies then Predict the Breakout
On July 5th, 2025, we screened 640 biotechnology companies to detect financial signals that often precede significant price movement. The filters results follow:
1,195
Cash Runway Risk
1,092
High R&D to Revenue
913
Revenue Growth Acceleration
823
Revenue Spike ≥20%
610
Net Income Breakout
610
Loss Reversal
Each flag represents a measurable change in fundamentals that may indicate an emerging catalyst. Companies are ranked by how many of these indicators they’ve triggered and how rare each signal is relative to their peers. This process allows us to focus on the most promising candidates for deeper analysis and prediction.
ScanScor is built to forecast potential breakouts across the entire biomedical industry. We have designed a system to keep news and data up to date for all tracked companies, enabling us to run fresh predictions as new catalysts emerge. Look for ScanScor reports highlighting companies with approaching catalyst dates and the potential for significant moves.
View the Reports Listings Page